Statement of Organization, Functions, and Delegations of Authority, 28124-28126 [E8-10637]
Download as PDF
<![CDATA[
28124
Federal Register / Vol. 73, No. 95 / Thursday, May 15, 2008 / Notices
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group; Biological Aging
Review Committee.
Date: June 5, 2008.
Time: 11 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Room 2C212, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Bita Nakhai, PhD,
Scientific Review Administrator, Scientific
Review Office, National Institute on Aging,
Gateway Bldg., 2c212, 7201 Wisconsin
Avenue, Bethesda, MD 20814, 301–402–
7701, nakhaib@nia.nih.gov.
Name of Committee: National Institute on
Aging Initial Review Group, Clinical Aging
Review Committee.
Date: June 5–6, 2008.
Time: 6 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Hotel, 4300 Military
Road, Washington, DC 20015.
Contact Person: Alicja L. Markowska, PhD,
DSC, National Institute on Aging, National
Institutes of Health, Gateway Building 2c212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666,
markowsa@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: May 7, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–10673 Filed 5–14–08; 8:45 am]
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; HRS 2010
Data Collection Supplement.
Date: June 5, 2008.
Time: 4 p.m. to 5:15 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015 (Telephone
Conference Call).
Contact Person: Jon E. Rolf, PhD, Scientific
Review Administrator, Scientific Review
Office, National Institute on Aging, Bethesda,
MD 20814, (301) 402–7703, rolfj@nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; The
Metabolic Syndrome of Aging.
Date: June 19, 2008.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue
Suite 2C212, Bethesda, MD 20814
(Telephone Conference Call).
Contact Person: Elaine Lewis, PhD,
Scientific Review Administrator, Scientific
Review Office, National Institute on Aging,
Gateway Building, Suite 2C212, MSC–9205,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–402–7707,
elainelewis@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: May 7, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–10675 Filed 5–14–08; 8:45 am]
BILLING CODE 4140–01–M
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
mstockstill on PROD1PC66 with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Statement of Organization, Functions,
and Delegations of Authority
National Institute on Aging; Notice of
Closed Meetings
The Statement of Organization,
Functions, and Delegations of Authority
Part N, National Institutes of Health
(NIH), of the Statement of Organization,
Functions, and Delegations of Authority
for the Department of Health and
Human Services (DHHS) (40 FR 22859,
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
VerDate Aug<31>2005
16:18 May 14, 2008
Jkt 214001
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
May 27, 1975, as amended most recently
at 71 FR 46495, August 14, 2006, and
redesignated from Part HN as Part N at
60 FR 56605, November 9, 1995), is
amended as set forth below to reflect the
establishment of the Division of
Program Coordination, Planning, and
Strategic Initiatives (DPCPSI), National
Institutes of Health. The National
Institutes of Health Reform Act of 2006
(Pub. L. 109–482) establishes and
provides the authorities of DPCPSI and
transfers the following organizations in
their entirety to DPCPSI: Office of AIDS
Research (OAR); Office of Research on
Women’s Health (ORWH); Office of
Behavioral and Social Sciences
Research (OBSSR); Office of Disease
Prevention (ODP); Office of Dietary
Supplements (ODS); Office of Rare
Diseases (ORD), to be retitled as the
Office of Rare Diseases Research
(ORDR). Also transferring to DPCPSI are
the Office of Portfolio Analysis and
Strategic Initiatives (OPASI), Division of
Resource Development and Analysis
(DRDA), Division of Strategic
Coordination (DSC), Division of
Evaluation and Systematic Assessments
(DESA), and Office of Medical
Applications of Research (OMAR), ODP.
The following organizations are
abolished: OAR; ORWH; OBSSR; ODP;
ODS, ODP; ORD, ODP; OMAR, ODP;
and OPASI.
I. Section N–B, Organization and
Functions, is amended as follows:
A. Immediately after the paragraph
headed ‘‘NIH Ethics Office (NAT,
formerly HNAT)’’ insert the following:
Division of Program Coordination,
Planning, and Strategic Initiatives (NA
W, formerly HNA 149). (1) Identifies and
reports on research that represents
important areas of emerging scientific
opportunities, rising public health
challenges, or knowledge gaps that
deserve special emphasis and would
benefit from conducting or supporting
additional research that involves
collaboration between two or more
Institutes and Centers (ICs), or would
otherwise benefit from strategic
coordination and planning; and (2)
coordinates research and activities
related to AIDS, behavioral and social
sciences, women’s health, disease
prevention, rare diseases, and dietary
supplements.
Office of AIDS Research (NA W2,
formerly HNA W2). (1) Develops a
comprehensive strategic plan that
identifies and establishes objectives,
priorities, and policy statements
governing the conduct and support of
all NIH AIDS research activities; (2)
develops and presents to OMB and the
President an annual scientifically
justified budget estimate for NIH AIDS-
E:\FR\FM\15MYN1.SGM
15MYN1
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 73, No. 95 / Thursday, May 15, 2008 / Notices
related research activities; (3) submits
an alternate AIDS budget to the
Secretary and the Director, NIH, in
accordance with the strategic plan; (4)
receives and disburses all appropriated
funds for NIH AIDS research activities
to the NIH ICs in accordance with the
strategic plan; (5) directs the planning,
coordination, and integration of all
AIDS research activities across and
throughout the NIH ICs; (6) evaluates
NIH HIV/AIDS research programs
developed for the strategic plan and
carried out by the ICs; (7) administers a
discretionary fund for the support,
through the ICs, of AIDS research; (8)
advises the NIH director and senior staff
on the development of NIH-wide policy
issues related to AIDS research, and
serves as principal liaison with HHS
Operating Divisions (OPDIVs) and Staff
Divisions (STAFFDIVs), other Federal
Government agencies, and the Office for
National AIDS Policy; (9) represents the
NIH director on all outside AIDS-related
committees requiring NIH participation;
(10) provides staff support to the OAR
Advisory Council, NIH AIDS Executive
Committee, and the Coordinating
Committees for each AIDS research
discipline at NIH; (11) develops policy
on laboratory safety for AIDS
researchers and monitors the AIDS
surveillance program; (12) develops and
maintains an information database on
intramural/extramural AIDS activities
and prepares special or recurring reports
as needed; (13) develops information
strategies to assure that the public is
informed of NIH AIDS research
activities; (14) recommends solutions to
ethical and legal issues arising from NIH
intramural/extramural AIDS research;
(15) facilitates collaboration in AIDS
research between government, industry,
and educational institutions; and (16)
fosters and develops plans for NIH
involvement in international AIDS
research activities.
Office of Research on Women’s Health
(NA W3, formerly HNA W3). (1) Advises
the NIH Director, DPCPSI Director, and
other key officials on matters relating to
research on women’s health; (2)
strengthens and enhances research
related to diseases, disorders, and
conditions that affect women; (3)
ensures that research conducted and
supported by NIH adequately addresses
issues regarding women’s health; (4)
ensures that women are appropriately
represented in biomedical and
biobehavioral research studies
supported by the NIH; (5) develops
opportunities for and supports
recruitment, retention, reentry, and
advancement of women in biomedical
VerDate Aug<31>2005
16:18 May 14, 2008
Jkt 214001
careers; and (6) supports research on
women’s health issues.
Office of Behavioral and Social
Sciences Research (NA W4, formerly
HNA W4). (1) Advises the NIH Director,
DPCPSI Director, and other key officials
on matters relating to research on the
role of human behavior in the
development of health, prevention of
disease, and therapeutic intervention;
(2) coordinates research projects in the
behavioral and social sciences
conducted or supported by the NIH ICs;
(3) identifies research projects that
deserve expanded effort and support by
the ICs; and (4) develops research
projects in cooperation with the ICs.
Office of Disease Prevention (NA W5,
formerly HNA W5). (1) Coordinates the
activities of disease prevention, rare
diseases, dietary supplements, and
medical applications of research, and
advises the NIH Director, DPCPSI
Director, and other key officials on the
following: (a) Research related to
disease prevention, and promotion of
disease prevention research; (b) research
related to dietary supplements and their
role in disease prevention; (c) research
and activities related to rare diseases;
and (d) medical applications of
research, including drugs, procedures,
devices and other technology developed
from basic biomedical research at NIH;
(2) provides guidance to the research
institutes on research related to disease
prevention; (3) coordinates and
facilitates the systematic identification
of research activities pertinent to all
aspects of disease prevention, including:
(a) Identification of risk factors for
disease; (b) risk assessment,
identification, and development of
biologic, environmental, and behavioral
interventions to prevent disease
occurrence or progression of
presymptomatic disease; and (c) the
conduct of field trials and
demonstrations to assess interventions
and encourage their adoption, if
warranted; (4) identifies, coordinates,
and encourages fundamental research
aimed at elucidating the chain of
causation of acute and chronic diseases;
(5) coordinates and facilitates clinically
relevant NIH-sponsored research
bearing on disease prevention,
including interventions to prevent the
progression of detectable but
asymptomatic disease; (6) promotes the
coordinating linkage for research
institutes on biobehavioral modification
toward prevention of disease; (7)
coordinates with OMAR to promote the
effective transfer of identified safe and
efficacious preventive interventions to
the health care community and the
public; (8) works with the research
institutes to initiate and develop
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
28125
Request for Applications (RFA),
Program Announcements (PA), and
Requests for Proposals (RFP) to enhance
disease prevention program
development; and sponsors, singly or in
combination with other organizations,
workshops and conferences on disease
prevention; (9) provides a link between
the disease prevention and health
promotion activities of the research
institutes of the NIH, the Surgeon
General and Assistant Secretary for
Health, and the Secretary, (10) monitors
the effectiveness and progress of disease
prevention and health promotion
activities of the NIH; and (11) reports
expenditures and personnel involved in
prevention activities at NIH.
Office of Dietary Supplements (NA
W52, formerly HNA W52). (1) Advises
the Associate Director for Disease
Prevention and provides guidance to the
research institutes on research related to
the health benefits of dietary
supplements and their role in disease
prevention; (2) conducts, promotes, and
coordinates research at NIH relating to
dietary supplements; (3) collects and
compiles the results of scientific
research relating to dietary
supplements; (4) serves as principal
advisor to the Secretary and PHS
components on non-regulatory issues
relating to dietary supplements; and (5)
compiles and maintains a database of
scientific research and funding.
Office of Rare Diseases Research (NA
W53, formerly HNA W53). (1) Guides
and coordinates NIH-wide activities
involving research into combating and
treating the broad array of rare diseases
(orphan diseases); (2) manages the NIH
Rare Diseases and Orphan Products
Coordinating Committee; (3) develops
and maintains a centralized database on
rare diseases; (4) coordinates and
provides liaison with Federal and nonFederal national and international
organizations concerned with rare
disease research and orphan products
development; (5) advises the Office of
the Director, NIH, on matters relating to
NIH-sponsored research activities that
involve rare diseases and conditions;
and (6) responds to requests for
information on highly technical matters
and matters of public policy relative to
rare diseases and orphan products.
Office of Medical Applications of
Research (NA W54, formerly HNA W54).
(1) Advises the Associate Director for
Disease Prevention and provides
guidance to the research institutes on
medical applications of research; (2)
coordinates, reviews, and facilitates the
systematic identification and evaluation
of clinically relevant NIH research
program information; (3) promotes the
effective transfer of this information to
E:\FR\FM\15MYN1.SGM
15MYN1
mstockstill on PROD1PC66 with NOTICES
28126
Federal Register / Vol. 73, No. 95 / Thursday, May 15, 2008 / Notices
the health care community and, through
the Office of Health Technology
Assessment, National Center for Health
Services Research and Health Care
Technology Assessment (NCHSRHCTA),
to those agencies requiring this
information; (4) provides a link between
technology assessment activities of the
research institutes of the NIH and the
NCHSRHCTA; and (5) monitors the
effectiveness and progress of the
assessment and transfer activities of the
NIH.
Office of Portfolio Analysis and
Strategic Initiatives (NA W6, formerly
HNA W6). Supports regular trans-NIH
scientific planning and initiatives and
the successful and adaptive priority
setting process for identifying areas of
scientific and health improvement
opportunities.
Division of Resource Development
and Analysis (NA W62, formerly HNA
W62). (1) Uses resources (databases,
analytic tools, and methodologies) and
develops specifications for new
resources, when needed, to conduct
assessments based on NIH and other
databases in support of portfolio
analyses and priority setting in
scientific areas of interest across NIH;
(2) serves as a resource for portfolio
management at the programmatic level;
and (3) ensures that NIH addresses
important areas of emerging scientific
opportunities and public health
challenges effectively.
Division of Strategic Coordination
(NA W63, formerly HNA W63). (1)
Integrates information and develops
recommendations to inform NIH’s
priority-setting and decision making
processes with respect to strategic
initiatives; (2) addresses exceptional
scientific opportunities and emerging
public health needs; (3) provides the
NIH Director with the information
needed to allocate resources effectively
for trans-NIH efforts; and (4) identifies
trans-NIH initiatives for consideration
and evaluation by both outside advisors
and NIH leadership.
Division of Evaluation and Systematic
Assessments (NA W64, formerly HNA
W64). Plans, conducts, coordinates, and
supports program evaluations,
including, but not limited to, IC specific
program and project evaluations; transNIH evaluations, including Roadmap
initiatives; and systematic assessments
required by the Government
Performance and Results Act and the
OMB Program Assessment Rating Tool.
II. Under the heading ‘‘Office of the
Director (NA, formerly HNA)’’ delete in
their entirety the following headed
paragraphs: ‘‘Office of Research on
Women’s Health (NAG, formerly
HNAG)’’; the ‘‘Office of AIDS Research
VerDate Aug<31>2005
16:18 May 14, 2008
Jkt 214001
(NA5, formerly HNA5)’’; the ‘‘Office of
Behavioral and Social Sciences
Research (NAH, formerly HNAH)’’; the
‘‘Office of Disease Prevention (NA2,
formerly HNA2)’’; the ‘‘Office of
Medical Applications of Research
(NA23, formerly HNA23)’’; the ‘‘Office
of Dietary Supplements (NA25, formerly
HNA25)’’; the ‘‘Office of Rare Diseases
(NA26, formerly HNA26)’’; the ‘‘Office
of Portfolio Analysis and Strategic
Initiatives (NAU, formerly HNAU)’’; the
‘‘Division of Resource Development and
Analysis (NA, formerly HNAU2)’’; the
‘‘Division of Strategic Coordination
(NAU3, formerly HNAU3)’’; and the
‘‘Division of Evaluation and Systematic
Assessments (NAU4, formerly
HNAU4).’’
III. Delegations of Authority: All
delegations and redelegations of
authority to officers and employees of
NIH which were in effect immediately
prior to the effective date of this
reorganization and are consistent with
this reorganization shall continue in
effect in them or their successors,
pending further redelegation.
Dated: May 6, 2008.
Michael O. Leavitt,
Secretary.
[FR Doc. E8–10637 Filed 5–14–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Opioid Treatment Programs
(OTPs) Mortality Reporting Form—
NEW
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Substance Abuse
Treatment (CSAT), has developed a
voluntary reporting form for Opioid
Treatment Programs (OTPs) to report
mortality data on patients who at the
time of death, were enrolled in the
Programs that were certified to operate
by SAMHSA.
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Methadone is a Schedule II controlled
substance approved by the Food and
Drug Administration for the treatment of
opioid dependence and pain. Although
it has been proven safe and effective, it
must be carefully administered and for
that reason, treatment of opioid
dependence with methadone is
provided only through specialized and
Federally regulated and accredited
clinics, the OTPs. Buprenorphine, a
Schedule III controlled substance, is
also used in the treatment of opioid
addiction by OTPs and office-based
physicians.
In recent years, methadone has been
associated with an increasing number of
deaths around the country.
Simultaneously, the use of methadone
for pain has increased significantly over
the last 5 to 10 years. While the Food
and Drug Administration (FDA)
maintains oversight of methadone for
use in pain, SAMHSA provides
oversight of methadone for use in opioid
addiction treatment. Currently, there is
no national database that tracks
mortality among patients receiving
methadone in OTPs and as a result, it
is not clear whether and to what extent
the increase in methadone-associated
deaths may be related to treatment in
OTPs. MedWatch, a voluntary reporting
system maintained by FDA, provides
information relevant to its role in its
more general oversight of medication
and device safety. A similar system is
needed within SAMHSA to gather
information directly relevant to the
agency’s mission of overseeing and
ensuring safe and effective treatment for
patients with opioid dependence.
In order to more accurately
understand potential methadoneassociated deaths at the OTP level, it is
necessary to examine all patient deaths,
including those related to
buprenorphine. Understanding the
actual cause of death of patients
enrolled in OTPs can be a challenging
task for many reasons, including
inconsistencies in methods of reporting
causes of deaths across different
localities and officials; patients’ use of
other drugs, including illicit, over-thecounter, and prescription products; and
other aspects of the patient’s physical
and mental condition. The standardized
terminology to be used for reporting in
the proposed system will contribute to
a more precise and relevant analysis of
individual cases and higher-level
trends. The data will be used by
SAMHSA to increase understanding of
the factors contributing to these deaths,
identify preventable causes of deaths,
and ultimately, take appropriate action
to minimize risk and help improve the
quality of care. Importantly, better data
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 73, Number 95 (Thursday, May 15, 2008)]
[Notices]
[Pages 28124-28126]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-10637]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Statement of Organization, Functions, and Delegations of
Authority
The Statement of Organization, Functions, and Delegations of
Authority Part N, National Institutes of Health (NIH), of the Statement
of Organization, Functions, and Delegations of Authority for the
Department of Health and Human Services (DHHS) (40 FR 22859, May 27,
1975, as amended most recently at 71 FR 46495, August 14, 2006, and
redesignated from Part HN as Part N at 60 FR 56605, November 9, 1995),
is amended as set forth below to reflect the establishment of the
Division of Program Coordination, Planning, and Strategic Initiatives
(DPCPSI), National Institutes of Health. The National Institutes of
Health Reform Act of 2006 (Pub. L. 109-482) establishes and provides
the authorities of DPCPSI and transfers the following organizations in
their entirety to DPCPSI: Office of AIDS Research (OAR); Office of
Research on Women's Health (ORWH); Office of Behavioral and Social
Sciences Research (OBSSR); Office of Disease Prevention (ODP); Office
of Dietary Supplements (ODS); Office of Rare Diseases (ORD), to be
retitled as the Office of Rare Diseases Research (ORDR). Also
transferring to DPCPSI are the Office of Portfolio Analysis and
Strategic Initiatives (OPASI), Division of Resource Development and
Analysis (DRDA), Division of Strategic Coordination (DSC), Division of
Evaluation and Systematic Assessments (DESA), and Office of Medical
Applications of Research (OMAR), ODP. The following organizations are
abolished: OAR; ORWH; OBSSR; ODP; ODS, ODP; ORD, ODP; OMAR, ODP; and
OPASI.
I. Section N-B, Organization and Functions, is amended as follows:
A. Immediately after the paragraph headed ``NIH Ethics Office (NAT,
formerly HNAT)'' insert the following:
Division of Program Coordination, Planning, and Strategic
Initiatives (NA W, formerly HNA 149). (1) Identifies and reports on
research that represents important areas of emerging scientific
opportunities, rising public health challenges, or knowledge gaps that
deserve special emphasis and would benefit from conducting or
supporting additional research that involves collaboration between two
or more Institutes and Centers (ICs), or would otherwise benefit from
strategic coordination and planning; and (2) coordinates research and
activities related to AIDS, behavioral and social sciences, women's
health, disease prevention, rare diseases, and dietary supplements.
Office of AIDS Research (NA W2, formerly HNA W2). (1) Develops a
comprehensive strategic plan that identifies and establishes
objectives, priorities, and policy statements governing the conduct and
support of all NIH AIDS research activities; (2) develops and presents
to OMB and the President an annual scientifically justified budget
estimate for NIH AIDS-
[[Page 28125]]
related research activities; (3) submits an alternate AIDS budget to
the Secretary and the Director, NIH, in accordance with the strategic
plan; (4) receives and disburses all appropriated funds for NIH AIDS
research activities to the NIH ICs in accordance with the strategic
plan; (5) directs the planning, coordination, and integration of all
AIDS research activities across and throughout the NIH ICs; (6)
evaluates NIH HIV/AIDS research programs developed for the strategic
plan and carried out by the ICs; (7) administers a discretionary fund
for the support, through the ICs, of AIDS research; (8) advises the NIH
director and senior staff on the development of NIH-wide policy issues
related to AIDS research, and serves as principal liaison with HHS
Operating Divisions (OPDIVs) and Staff Divisions (STAFFDIVs), other
Federal Government agencies, and the Office for National AIDS Policy;
(9) represents the NIH director on all outside AIDS-related committees
requiring NIH participation; (10) provides staff support to the OAR
Advisory Council, NIH AIDS Executive Committee, and the Coordinating
Committees for each AIDS research discipline at NIH; (11) develops
policy on laboratory safety for AIDS researchers and monitors the AIDS
surveillance program; (12) develops and maintains an information
database on intramural/extramural AIDS activities and prepares special
or recurring reports as needed; (13) develops information strategies to
assure that the public is informed of NIH AIDS research activities;
(14) recommends solutions to ethical and legal issues arising from NIH
intramural/extramural AIDS research; (15) facilitates collaboration in
AIDS research between government, industry, and educational
institutions; and (16) fosters and develops plans for NIH involvement
in international AIDS research activities.
Office of Research on Women's Health (NA W3, formerly HNA W3). (1)
Advises the NIH Director, DPCPSI Director, and other key officials on
matters relating to research on women's health; (2) strengthens and
enhances research related to diseases, disorders, and conditions that
affect women; (3) ensures that research conducted and supported by NIH
adequately addresses issues regarding women's health; (4) ensures that
women are appropriately represented in biomedical and biobehavioral
research studies supported by the NIH; (5) develops opportunities for
and supports recruitment, retention, reentry, and advancement of women
in biomedical careers; and (6) supports research on women's health
issues.
Office of Behavioral and Social Sciences Research (NA W4, formerly
HNA W4). (1) Advises the NIH Director, DPCPSI Director, and other key
officials on matters relating to research on the role of human behavior
in the development of health, prevention of disease, and therapeutic
intervention; (2) coordinates research projects in the behavioral and
social sciences conducted or supported by the NIH ICs; (3) identifies
research projects that deserve expanded effort and support by the ICs;
and (4) develops research projects in cooperation with the ICs.
Office of Disease Prevention (NA W5, formerly HNA W5). (1)
Coordinates the activities of disease prevention, rare diseases,
dietary supplements, and medical applications of research, and advises
the NIH Director, DPCPSI Director, and other key officials on the
following: (a) Research related to disease prevention, and promotion of
disease prevention research; (b) research related to dietary
supplements and their role in disease prevention; (c) research and
activities related to rare diseases; and (d) medical applications of
research, including drugs, procedures, devices and other technology
developed from basic biomedical research at NIH; (2) provides guidance
to the research institutes on research related to disease prevention;
(3) coordinates and facilitates the systematic identification of
research activities pertinent to all aspects of disease prevention,
including: (a) Identification of risk factors for disease; (b) risk
assessment, identification, and development of biologic, environmental,
and behavioral interventions to prevent disease occurrence or
progression of presymptomatic disease; and (c) the conduct of field
trials and demonstrations to assess interventions and encourage their
adoption, if warranted; (4) identifies, coordinates, and encourages
fundamental research aimed at elucidating the chain of causation of
acute and chronic diseases; (5) coordinates and facilitates clinically
relevant NIH-sponsored research bearing on disease prevention,
including interventions to prevent the progression of detectable but
asymptomatic disease; (6) promotes the coordinating linkage for
research institutes on biobehavioral modification toward prevention of
disease; (7) coordinates with OMAR to promote the effective transfer of
identified safe and efficacious preventive interventions to the health
care community and the public; (8) works with the research institutes
to initiate and develop Request for Applications (RFA), Program
Announcements (PA), and Requests for Proposals (RFP) to enhance disease
prevention program development; and sponsors, singly or in combination
with other organizations, workshops and conferences on disease
prevention; (9) provides a link between the disease prevention and
health promotion activities of the research institutes of the NIH, the
Surgeon General and Assistant Secretary for Health, and the Secretary,
(10) monitors the effectiveness and progress of disease prevention and
health promotion activities of the NIH; and (11) reports expenditures
and personnel involved in prevention activities at NIH.
Office of Dietary Supplements (NA W52, formerly HNA W52). (1)
Advises the Associate Director for Disease Prevention and provides
guidance to the research institutes on research related to the health
benefits of dietary supplements and their role in disease prevention;
(2) conducts, promotes, and coordinates research at NIH relating to
dietary supplements; (3) collects and compiles the results of
scientific research relating to dietary supplements; (4) serves as
principal advisor to the Secretary and PHS components on non-regulatory
issues relating to dietary supplements; and (5) compiles and maintains
a database of scientific research and funding.
Office of Rare Diseases Research (NA W53, formerly HNA W53). (1)
Guides and coordinates NIH-wide activities involving research into
combating and treating the broad array of rare diseases (orphan
diseases); (2) manages the NIH Rare Diseases and Orphan Products
Coordinating Committee; (3) develops and maintains a centralized
database on rare diseases; (4) coordinates and provides liaison with
Federal and non-Federal national and international organizations
concerned with rare disease research and orphan products development;
(5) advises the Office of the Director, NIH, on matters relating to
NIH-sponsored research activities that involve rare diseases and
conditions; and (6) responds to requests for information on highly
technical matters and matters of public policy relative to rare
diseases and orphan products.
Office of Medical Applications of Research (NA W54, formerly HNA
W54). (1) Advises the Associate Director for Disease Prevention and
provides guidance to the research institutes on medical applications of
research; (2) coordinates, reviews, and facilitates the systematic
identification and evaluation of clinically relevant NIH research
program information; (3) promotes the effective transfer of this
information to
[[Page 28126]]
the health care community and, through the Office of Health Technology
Assessment, National Center for Health Services Research and Health
Care Technology Assessment (NCHSRHCTA), to those agencies requiring
this information; (4) provides a link between technology assessment
activities of the research institutes of the NIH and the NCHSRHCTA; and
(5) monitors the effectiveness and progress of the assessment and
transfer activities of the NIH.
Office of Portfolio Analysis and Strategic Initiatives (NA W6,
formerly HNA W6). Supports regular trans-NIH scientific planning and
initiatives and the successful and adaptive priority setting process
for identifying areas of scientific and health improvement
opportunities.
Division of Resource Development and Analysis (NA W62, formerly HNA
W62). (1) Uses resources (databases, analytic tools, and methodologies)
and develops specifications for new resources, when needed, to conduct
assessments based on NIH and other databases in support of portfolio
analyses and priority setting in scientific areas of interest across
NIH; (2) serves as a resource for portfolio management at the
programmatic level; and (3) ensures that NIH addresses important areas
of emerging scientific opportunities and public health challenges
effectively.
Division of Strategic Coordination (NA W63, formerly HNA W63). (1)
Integrates information and develops recommendations to inform NIH's
priority-setting and decision making processes with respect to
strategic initiatives; (2) addresses exceptional scientific
opportunities and emerging public health needs; (3) provides the NIH
Director with the information needed to allocate resources effectively
for trans-NIH efforts; and (4) identifies trans-NIH initiatives for
consideration and evaluation by both outside advisors and NIH
leadership.
Division of Evaluation and Systematic Assessments (NA W64, formerly
HNA W64). Plans, conducts, coordinates, and supports program
evaluations, including, but not limited to, IC specific program and
project evaluations; trans-NIH evaluations, including Roadmap
initiatives; and systematic assessments required by the Government
Performance and Results Act and the OMB Program Assessment Rating Tool.
II. Under the heading ``Office of the Director (NA, formerly HNA)''
delete in their entirety the following headed paragraphs: ``Office of
Research on Women's Health (NAG, formerly HNAG)''; the ``Office of AIDS
Research (NA5, formerly HNA5)''; the ``Office of Behavioral and Social
Sciences Research (NAH, formerly HNAH)''; the ``Office of Disease
Prevention (NA2, formerly HNA2)''; the ``Office of Medical Applications
of Research (NA23, formerly HNA23)''; the ``Office of Dietary
Supplements (NA25, formerly HNA25)''; the ``Office of Rare Diseases
(NA26, formerly HNA26)''; the ``Office of Portfolio Analysis and
Strategic Initiatives (NAU, formerly HNAU)''; the ``Division of
Resource Development and Analysis (NA, formerly HNAU2)''; the
``Division of Strategic Coordination (NAU3, formerly HNAU3)''; and the
``Division of Evaluation and Systematic Assessments (NAU4, formerly
HNAU4).''
III. Delegations of Authority: All delegations and redelegations of
authority to officers and employees of NIH which were in effect
immediately prior to the effective date of this reorganization and are
consistent with this reorganization shall continue in effect in them or
their successors, pending further redelegation.
Dated: May 6, 2008.
Michael O. Leavitt,
Secretary.
[FR Doc. E8-10637 Filed 5-14-08; 8:45 am]
BILLING CODE 4140-01-M
